http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
위암에서의 p14<SUP>ARF</SUP>, p16<SUP>INK4a</SUP>, p53, pRb 단백 발현
채병주(Byung Joo Chae),송교영(Gyo Young Song),김진조(Jin Jo Kim),진형민(Hyung Min Chin),김욱(Wook Kim),박조현(Cho Hyun Park),전해명(Hae Myung Jeon),박승만(Seung Man Park),임근우(Keun Woo Lim),김응국(Eung Kook Kim),김승남(Seung Nam K 대한외과학회 2004 Annals of Surgical Treatment and Research(ASRT) Vol.67 No.2
채병주 ( Byung Joo Chae ),송병주 ( Byung Joo Song ),정상설 ( Sang Seol Jung ) 대한임상종양학회 2009 Korean Journal of Clinical Oncology Vol.5 No.1
배경 및 연구목적: 유방암은 조기 진단 및 근치적 절제술뿐만 아니라 수술 후 보조요법과 추적관리가 그 어떤 다른 고형암에서 보다 중요하다고 할 수 있다. 하지만, 얼마의 기간 동안, 어떠한 규칙과 검사법으로 추적관리를 해야 하는지에 대해서는 몇몇 국내외적 권고안이 있기는 하지만 통일되어 있지 않고 개별 의사마다 서로 다른 추적관리가 이루어지고 있는 실정이다. 따라서, 본 연구진은 국내에서 발생하는 유방암 암환자의 대부분을 치료하고 있는 한국유방암학회 회원을 대상으로 수술 후 치료전략 및 추적관리에 대한 설문조사를 통하여 현황을 알아보고자 하였다. 연구방법: 2008년 12월부터 2009년 2월까지 49개의 종합병원 급이상의 기관에서 환자진료를 담당하고 있는 한국유방암학회 회원 307명을 대상으로 e-mail과 우편을 통해 동시에 설문지를 발송하였으며 설문지를 회수하고 분석하였다. 설문은 응답자의 개인적인 사항과 추적검사를 시행하는 주체, 치료결정시 참고하는 권고안, 추적일정 등에 대한 질문으로 구성되었다. 연구결과: 응답자들은 30대부터 50대에 고른 연령분포를 보였으며 대부분 500병상 이상의 대형병원에 근무하고 5년 이상의 임상경력을 가지고 있는 외과의사가 대다수를 차지하고 있었고, 수술 후 추적관리 주체는 항암치료 여부, 호르몬 치료 여부에 상관없이 대부분의 경우 외과인 것으로 나타났으며 보조요법 결정 시에는 응답자 별로 다양한 권고안을 비슷한 비율로 참고하고 있었다. 또한, 추적검사일정은 수술 후부터 5년 사이에는 6개월 마다, 5년 후에는 1년 마다 한다는 응답이 대다수였고, 검사 항목으로는 단순유방촬영술, 유방초음파, 골스캔을 필수적으로 시행하며 PET CT와 MRI가 선택적으로 시행되고 CA 15-3, CEA 등의 종양표지자와 몇 가지 혈액화학검사를 필수적으로 시행되고 있는 것으로 나타났다. 결론: 국내 유방암 환자의 대부분을 진료하고 있는 유방암학회 정회원을 대상으로 하여 유방암 수술 후 보조요법 결정 및 추적관리현황에 대한 현황을 조사하여 몇몇 국내의 특징적인 현황들을 발견하였으며 이를 토대로 향후 필요한 연구의 방향을 제시하고 현재의 국내 권고안을 넘어선 추적관리 및 전반적인 치료법의 표준화를 이루기 위한 근거자료로 활용될 수 있을 것으로 생각된다. Introduction: The risk for recurrence of breast cancer continues over 15 years. So, adjuvant therapy and follow up examination in breast cancer are very important after surgery. We investigated current practice of post operative follow up management for breast cancer after curative resection through nationwide survey in Korea. Method: From December 2008 to February 2009, a questionnaire was sent out to 307 members of Korean Breast Cancer Society (KBCS). A questionnaire was composed of cover letter, general information and main questionnaire about follow-up schedules and contents. Results: 21.2% (65/307) of the members of the KBCS returned the survey. Most common responders described that subject of follow up was department of surgery with or without adjuvant chemotherapy. Reference guidelines for decision of adjuvant therapy were similar in distribution among NCCN, ASCO and KBCS guidelines. Most common follow up schedule was every 6months exam for first 5 years after primary surgery and then annually exam. Mammogram, sonogram, bone scan were tend to consider essentially and PET CT, MRI were considered alternatively. CA15-3, CEA and some of blood chemistry were also essential orders in most responders. Conclusions: It seems that clinicians treating breast cancer in Korea showed some different trend with international guidelines. Therefore, a multicenter randomized trial is needed to confirm the different modality for follow up and our results could give an aid to design such study.
채병주(Byung Joo Chae),송병주(Byung Joo Song),김신선(Sin Sun Kim),김성근(Sung Keun Kim),전경화(Kyong Hwa Jun),송교영(Kyo Yung Song),진형민(Hyung Min Chin),김욱(Wook Kim),박조현(Cho Hyun Park),박승만(Seung Man Park),임근우(Keun Woo L 대한외과학회 2007 Annals of Surgical Treatment and Research(ASRT) Vol.72 No.5
Purpose: Complementary and alternative medicine (CAM) has recently been spotlighted, and CAM can be defined as methods for treating diseases or ways to maintain physical health that out lie outside the boundaries of conventional medicine. We have conducted research to determine the status of CAM usage among Korean gastric cancer patients and their attitudes toward it, to determine what better can be done about CAM. Methods: We surveyed those patients in St. Mary Hospital who were diagnosed to gastric cancer and who volunteered to participate in this study. The survey consists of 38 questions and each question covered personal characteristics information as to whether they have used CAM, whether they were satisfied after taking CAM and their intentions for re-use. Results: A total of 195 patients answered the survey. 80 patients (41%) experienced CAM for the purpose of remedying their gastric cancer. The top leading CAM was dietary supplement for 52% of the patients, ginseng for 26% of the patients and Chinese herbal medicine for 10.8% of the patients. 54 patients (67.5%) were satisfied with the results of the CAM and they said that it had an effect on fatigue (45%). The statistics showed positive correlation between the level of education and the CAM users (P=0.001). Conclusion: The percentage of patients using CAM among the gastric cancer patients was high, up to 41%. Most of these patients wanted more information and discussion with their physicians about CAM therapies. The interesting thing was that most of the CAM was oral medicine. Based on our findings, research on the safety and effectiveness of CAM is required.
절제 불가능한 국소 진행성 위암 환자에서 Taxotere 및 Cisplatin을 이용한 선행 화학 요법제의 투여 후 근치적 절제가 가능했던 2예
이한홍,허훈,채병주,김욱,전해명,Lee, Han-Hong,Hur, Hoon,Chae, Byung-Joo,Kim, Wook,Jeon, Hae-Myung 대한위암학회 2005 대한위암학회지 Vol.5 No.1
위암의 치료에 있어서 근치적 절제는 완치를 위한 유일한 방법이나 불행이도 많은 환자들이 국소적이나 혹은 타 장기로 전이된 상태로 발견된다. 이런 경우에는 근치적 절제술의 시행이 매우 어렵고 선행 화학요법을 시행하여 병기를 낮추려는 시도가 고려되어야 한다. Docetaxel은 반합성 택산으로 튜불린의 중합 반응을 유도하고 미세관의 해중합 반을을 방해함으로서 그 작용을 나타낸다. 현재 전이성 위암의 신행화학요법에서 docetaxel의 사용이 많이 시도되고 있고 그 반응률이 보고되고 있다. 본 교실에서는 docetsxel과 cisplatin 병용요법을 시행하여 전이성 위암의 부분 관해로 근치적 절제가 가응하였던 2예를 보고하는 바이다. At diagnosis, the majority of patients with gastric cancer are found to have local invasion or distant organ metastasis, even though the sole measure for a complete cure is a curative resection. A curative resection is hardly applicable for those with invasion and metastasis; thus, trials with neoadjuvant chemotherapy for downstaging the cancer should be considered. Docetaxel is a semisynthetic taxane that promotes tubulin polymerization and inhibits microtubule depolymerization. In recent studies, many metastatic gastric cancers were treated using neoadjuvant chemotherapy with docetaxel, and the response rates were reported. We report here two cases of locally advanced, non-resectable gastric cancer that were candidates for a curative resection after induction chemotherapy with docetaxel and cisplatin.
재발한 위장관 간질성 종양(GISTs) 환자들의 임상양상 분석
나건형(Gun Hyung Na),김영균(Young Kyun Kim),이한홍(Han Hong Lee),지성배(Sung Bae Ji),채병주(Byung Joo Chae),허훈(Hoon Hur),김욱(Wook Kim),전해명(Hae Myung Jeon) 대한외과학회 2007 Annals of Surgical Treatment and Research(ASRT) Vol.73 No.4
Purpose: Gastrointestinal stromal tumors (GISTs) are of a mesenchymal origin, and they arise predominantly from the gastrointestinal tract. This study aims to aid the post operative management of GIST patients by analyzing the clinical and immunopathological features of recurrent GISTs. Methods: We enrolled 98 GIST patients who had been operated on for their primary tumor from 1987 to 2001 at the Catholic Medical Center. Among them, 28 patients had clinical and radiological features that were proved to be recurrence, and the patients’ survival rates were compared according to the treatment modalities. Results: When the maximum length of tumor was shorter and the mitotic index lower, then these patients had higher disease free survival rates and lower recurrence rates. The Ki-67 negative group had lower recurrence rates than their Ki-67 positive counterparts. Recurrence was mostly observed as liver metastasis. The mean length of time to recur was 22.96 months. Fifteen patients received additional treatments such as surgery, chemotherapy and radiation therapy, but there was no significant difference in survival rates when they were compared to the 13 patients who did not receive further treatments. Conclusion: Of the patients diagnosed with GIST after surgery, those with worse prognostic factors, i.e. a bigger tumor size and higher mitotic index, require more meticulous surveillance for tumor recurrence, and especially for liver recurrence, which was the most common recurrence site, during the follow up exams. In addition, although there have not been any remarkably effective treatments for the recurrent GIST patients, further researches for new therapy such as STI-571 is mandated.